{
    "nctId": "NCT01696617",
    "officialTitle": "Aripiprazole (Abilify\u00ae) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder",
    "inclusionCriteria": "* Age : 18-65\n* Patients with major depressive disorder according to DSM-IV criteria that have lasted \\>8 weeks\n* MADRS total score of 18 or higher\n* Patients who responded inadequately (a score of \\>18 on the MADRS) to first-line antidepressant treatment of 4 week duration\n* Current use of standard antidepressant treatment in monotherapy or combination of 2 antidepressants : escitalopram (10 - 20mg/d), fluoxetine(20 - 40mg/d), paroxetine CR(25 - 50mg/d), sertraline(100 - 150mg/d), mirtazapine (15 - 45mg/d), duloxetine (30 - 60mg/d) or venlafaxine ER(150-225mg/d)\n* Must have minimum age of 18 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "* Past history of hypersensitivity to aripiprazole\n* Primary diagnosis of MDD with psychotic feature, bipolar disorder, schizophrenia, schizoaffective disorder, other psychotic disorder or anxiety disorder, a history of alcohol/ drug abuse within the past 12 months, or a diagnosis of dementia\n* Clinically significant current Axis II (DSM-IV-TR) diagnosis\n* A significant risk of suicide corroborated by a score of \u22655 on item 10(suicidal thoughts) on the MADRS scale or by clinical judgment of the investigator\n* Pregnancy or in breast-feeding\n* Presence of a serious medical illness including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease or physical disorder judged to significantly affect central nervous system function\n* Patients taking antipsychotics, mood stabilizer or any psychotropic medications besides antidepressants, except benzodiazepines or beta blockers or hypnotics\n* Patients with past treatment failures of aripiprazole"
}